Published in Respir Med on May 22, 2012
Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax (2013) 1.92
Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One (2015) 1.17
Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS One (2014) 0.97
Chronic obstructive pulmonary disease severity is associated with severe pneumonia. Ann Thorac Med (2015) 0.91
Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation (2013) 0.90
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS One (2013) 0.86
Community-acquired pneumonia and survival of critically ill acute exacerbation of COPD patients in respiratory intensive care units. Int J Chron Obstruct Pulmon Dis (2016) 0.85
Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One (2013) 0.84
Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. PLoS One (2014) 0.83
Costs and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumonia. Clinicoecon Outcomes Res (2014) 0.81
Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis. Int J Chron Obstruct Pulmon Dis (2014) 0.80
A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med (2016) 0.80
Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. PLoS One (2015) 0.79
Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J Chron Obstruct Pulmon Dis (2016) 0.78
THE PARADOXICAL EFFECT ON PNEUMONIA OF CHRONIC INHALED CORTICOSTEROIDS. Clin Pulm Med (2013) 0.78
Association between Image Characteristics on Chest CT and Severe Pleural Adhesion during Lung Cancer Surgery. PLoS One (2016) 0.78
Computer-aided diagnosis of pneumonia in patients with chronic obstructive pulmonary disease. J Am Med Inform Assoc (2013) 0.76
Determinants of noninvasive ventilation outcomes during an episode of acute hypercapnic respiratory failure in chronic obstructive pulmonary disease: the effects of comorbidities and causes of respiratory failure. Biomed Res Int (2014) 0.76
Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Association of COPD With Risk for Pulmonary Infections Requiring Hospitalization in HIV-Infected Veterans. J Acquir Immune Defic Syndr (2015) 0.75
The risk and outcomes of pneumonia in patients on inhaled corticosteroids. Pulm Pharmacol Ther (2015) 0.75
Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records. Int J Chron Obstruct Pulmon Dis (2017) 0.75
The association of renin-angiotensin system blockades and pneumonia requiring admission in patients with COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Community-acquired lower respiratory tract infections in HIV-infected patients on antiretroviral therapy: predictors in a contemporary cohort study. Infection (2017) 0.75
Irradiation enhanced risks of hospitalised pneumonopathy in lung cancer patients: a population-based surgical cohort study. BMJ Open (2017) 0.75
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med (2005) 7.58
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 4.87
Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 4.73
Chronic obstructive pulmonary disease. Lancet (2012) 4.43
Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 3.61
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 2.80
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2008) 2.66
Airway and systemic inflammation and decline in lung function in patients with COPD. Chest (2005) 2.59
The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest (2003) 2.44
Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.41
Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ (2004) 2.39
Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J (2012) 2.18
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med (2009) 2.17
Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest (2009) 2.16
Use and utility of a 24-hour Telephone Support Service for 'high risk' patients with COPD. Prim Care Respir J (2010) 2.14
Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest (2006) 2.06
The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest (2005) 2.04
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med (2006) 1.98
Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.90
Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis (2009) 1.85
Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 1.85
Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res (2010) 1.79
Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.77
Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.75
Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.73
Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol (2012) 1.68
Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med (2008) 1.68
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J (2011) 1.68
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Predictors of adverse outcome in patients hospitalised for exacerbation of chronic obstructive pulmonary disease. Respiration (2012) 1.62
Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur Respir J (2013) 1.62
Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. Cochrane Database Syst Rev (2012) 1.60
The higher the number of daily doses of antibiotic treatment in lower respiratory tract infection the worse the compliance. J Antimicrob Chemother (2008) 1.60
New horizons in early stage COPD--improving knowledge, detection and treatment. Respir Med (2011) 1.56
Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. Chest (2013) 1.51
Variability in the performing of spirometry and its consequences in the treatment of COPD in primary care. Arch Bronconeumol (2011) 1.50
Underdiagnosis of chronic obstructive pulmonary disease in women: quantification of the problem, determinants and proposed actions. Arch Bronconeumol (2013) 1.47
Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis (2012) 1.47
Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax (2012) 1.42
Outdoor air pollution and respiratory health in patients with COPD. Thorax (2011) 1.42
Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics (2005) 1.42
Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.40
[Variability of antibiotic prescribing for respiratory tract infections in two European countries]. Enferm Infecc Microbiol Clin (2005) 1.39
IL-1α/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One (2011) 1.37
Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. Prim Care Respir J (2010) 1.36
Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc (2006) 1.32
Time course and pattern of COPD exacerbation onset. Thorax (2011) 1.30
Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J (2008) 1.26
The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med (2015) 1.25
Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax (2011) 1.22
Controversies in treatment of chronic obstructive pulmonary disease. Lancet (2011) 1.16
Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med (2008) 1.15
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Determinants of Underdiagnosis of COPD in National and International Surveys. Chest (2015) 1.14
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ (2007) 1.13
Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2012) 1.10
COPD management: role of symptom assessment in routine clinical practice. Int J Chron Obstruct Pulmon Dis (2013) 1.09
Factors associated with change in exacerbation frequency in COPD. Respir Res (2013) 1.08
Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest (2005) 1.07
The general public's knowledge of chronic obstructive pulmonary disease and its determinants: current situation and recent changes. Arch Bronconeumol (2012) 1.06
Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med (2008) 1.04
Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med (2009) 1.02
Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med (2011) 1.01
Respiratory guidelines--which real world? Ann Am Thorac Soc (2014) 1.01
Factors associated with high healthcare resource utilisation among COPD patients. Respir Med (2012) 1.01
Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest (2009) 1.01
COPD symptoms in the morning: impact, evaluation and management. Respir Res (2013) 1.00
Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulm Med (2010) 0.99
Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res (2007) 0.98
[Impact of chronic obstructive pulmonary disease on activities of daily living: results of the EIME multicenter study]. Arch Bronconeumol (2007) 0.98
A cross-sectional study of household biomass fuel use among a periurban population in Malawi. Ann Am Thorac Soc (2014) 0.97
[Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors]. Arch Bronconeumol (2010) 0.96
Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest (2013) 0.95
Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. COPD (2007) 0.95
Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect (2013) 0.94
Viral infections in obstructive airway diseases. Curr Opin Pulm Med (2003) 0.93
25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. BMC Pulm Med (2012) 0.93
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). Respir Med (2004) 0.92
Spirometrically-defined restrictive ventilatory defect: population variability and individual determinants. Prim Care Respir J (2012) 0.91
Detection of polymorphisms at exons 3 (Tyr113-->His) and 4 (His139-->Arg) of the microsomal epoxide hydrolase gene using fluorescence PCR method combined with melting curves analysis. Anal Biochem (2002) 0.91
Rare alpha-1-antitrypsin variants: are they really so rare? Ther Adv Respir Dis (2012) 0.90
[Use of spirometry in the diagnosis and treatment of chronic obstructive pulmonary disease in primary care]. Arch Bronconeumol (2006) 0.90
Glutathione S-transferase P1 and lung function in patients with alpha1-antitrypsin deficiency and COPD. Chest (2005) 0.90
[Guidelines for the diagnosis and management of alpha-1 antitrypsin deficiency]. Arch Bronconeumol (2006) 0.89
Compliance with guidelines in the treatment of asthma exacerbations in primary care. Ther Adv Respir Dis (2011) 0.89
Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol (2005) 0.89
Reduced lung-cancer mortality with CT screening. N Engl J Med (2011) 0.89
Variability of respiratory symptoms in severe COPD. Arch Bronconeumol (2011) 0.89
Effects of whole body vibration training in patients with severe chronic obstructive pulmonary disease. Respirology (2013) 0.88
Rapid screening for alpha1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease using dried blood specimens. Am J Respir Crit Care Med (2002) 0.87